<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448524</url>
  </required_header>
  <id_info>
    <org_study_id>MiStent01</org_study_id>
    <nct_id>NCT02448524</nct_id>
  </id_info>
  <brief_title>Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)</brief_title>
  <acronym>DESSOLVE-C</acronym>
  <official_title>A Prospective, Single-blinded, Multi-center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-eluting Stent (MiStent® System) in the Treatment of Patients With Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Micell Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hefei Life Science Medical Instruments Co. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Giant Med-Pharma Services Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CCRF Consulting Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Micell Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the safety and efficacy of MiStent drug (sirolimus)-eluting stent system in&#xD;
           the treatment of coronary heart disease (CHD) in patients with primary in situ CHD (de&#xD;
           novo);&#xD;
&#xD;
        -  To evaluate operating performance of the MiStent drug (sirolimus)-eluting coronary stent&#xD;
           system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The study will enroll a total of 428 cases of primary in situ coronary artery disease&#xD;
           patients (all patients enrolled with a maximum of two target lesions in different blood&#xD;
           vessels and maximum of 2 stents per lesion. If more stents are needed for implantation,&#xD;
           stents with the same brand are required, and mixing brands is not allowed for each&#xD;
           patient except for salvage with implantation of other brand of stents.)&#xD;
&#xD;
        -  Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length&#xD;
           ≤40mm (by visual measurement) will be selected, subjects meeting the inclusion and&#xD;
           exclusion criteria and who agree to participate will be enrolled.&#xD;
&#xD;
        -  Prospective, single-blinded, multi-center, randomized, controlled clinical trial;&#xD;
&#xD;
        -  Patients with in situ primary CHD;&#xD;
&#xD;
        -  Clinical sites: up to 18; patients will be enrolled in a 1:1 ratio (i.e., 214 cases&#xD;
           enrolled into each group, the MiStent stent group and TIVOLI stent group);&#xD;
&#xD;
        -  Clinical follow-up time points: 1 month, 6 months, 9 months, 12 months and yearly at 2-5&#xD;
           years post index procedure;&#xD;
&#xD;
        -  Angiographic follow-up at 9 months post index procedure; in-stent late lumen loss&#xD;
           measured by quantitative coronary angiography (QCA) will be used as the primary efficacy&#xD;
           endpoint for product evaluation;&#xD;
&#xD;
        -  In this trial, the collection, collation, statistical analysis and adjudication of all&#xD;
           relevant clinical and angiographic data will be conducted by an independent coronary&#xD;
           angiography core laboratory (CCRF Medical Technology Co., Ltd.), data management and&#xD;
           statistical center, clinical events committee and clinical audit agency. All patients&#xD;
           will be followed up for 5 years (by telephone or outpatient form), and the incidence of&#xD;
           adverse events will be recorded to allow a more accurate and reliable evaluation of the&#xD;
           long-term safety of the MiStentTM drug (sirolimus) eluting coronary stent system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent late lumen loss (LLL)</measure>
    <time_frame>9 months post index procedure</time_frame>
    <description>Late lumen loss is the difference in millimeters between the diameter of a stented segment post-procedure compared with the follow-up angiogram at nine months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate of stent implantation (including device success, lesion success and clinical success);</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis rate in-stent, at proximal and distal edges of the stent and in-lesion segments; and late lumen loss and percent diameter stenosis in lesion segments</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-related clinical cardiovascular composite endpoints post index procedure, including cardiac death, target vessel myocardial infarction and clinical symptoms driven target lesion revascularization (i.e., target lesion failure [TLF])</measure>
    <time_frame>30 days, 6 months, 12 months, and 2-5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-related clinical cardiovascular composite endpoints post index procedure, including all-cause death (cardiac and non-cardiac), nonfatal myocardial infarction and any revascularization</measure>
    <time_frame>30 days, 6 months, 12 months and 2-5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ARC-defined stent thrombosis (definite, probable, possible stent thrombosis at early, late and very late periods)</measure>
    <time_frame>30 days, 6 months, 12 months and 2-5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-related adverse events of dual antiplatelet therapy (DAPT) post index procedure.</measure>
    <time_frame>30 days, 6 months, 12 months and 2-5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">428</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>MiStentTM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MiStentTM coronary drug eluting stent (MiStent SES) consists of four parts: a bare-metal stent (BMS), a delivery system, resorbable polymer coating and anti-proliferative drug (sirolimus).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIVOLI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TIVOLI stent is a mature and fully degradable coating on a cobalt-chromium alloy drug-eluting stent on the market, findings of four years fully demonstrated the efficacy and safety of sirolimus-coated TIVOLI stent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MiStent</intervention_name>
    <description>Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).</description>
    <arm_group_label>MiStentTM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TIVOLI</intervention_name>
    <description>Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).</description>
    <arm_group_label>TIVOLI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stable and unstable angina pectoris (AP), old myocardial infarction (OMI), or&#xD;
             confirmed evidence of myocardial ischemia;&#xD;
&#xD;
          -  Primary in situ coronary artery lesions (up to two target lesions and up to 2 stents&#xD;
             per lesion);&#xD;
&#xD;
          -  Visual target lesion length ≤40mm;&#xD;
&#xD;
          -  Visual reference vessel diameter of 2.5-3.5mm;&#xD;
&#xD;
          -  Visual diameter stenosis ≥70%;&#xD;
&#xD;
          -  Patients with indications for coronary artery bypass surgery (CABG);&#xD;
&#xD;
          -  Subjects participate voluntarily and signed an informed consent willing to accept&#xD;
             angiographic and clinical follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute myocardial infarction (AMI) occurred within 7 days prior to the procedure;&#xD;
             post-MI complicated with elevated levels of cardiac enzymes (CK-MB, cTNT / I);&#xD;
&#xD;
          -  CTO (TIMI-0) lesions, left main lesions, ostial lesions,bypass graft lesions,&#xD;
             bifurcation lesions (lateral side branch reference vessel diameter≥2.5mm), restenosis&#xD;
             in-stent and three-vessel disease that need to be treated;&#xD;
&#xD;
          -  Severe calcified lesions for which balloon pre-dilation is expected to be&#xD;
             unsuccessful;&#xD;
&#xD;
          -  Tortuous lesions that render stent crossing difficult;&#xD;
&#xD;
          -  NYHA class≥III or left ventricular ejection fraction &lt;40%;&#xD;
&#xD;
          -  Implantation of other stents in the past year;&#xD;
&#xD;
          -  Pregnant or breast-feeding patients or patients planning to get pregnant within the&#xD;
             following year;&#xD;
&#xD;
          -  Subjects with bleeding tendency or coagulation disorder or PCI contraindications and /&#xD;
             or anticoagulant therapy contraindications or who have not tolerated dual antiplatelet&#xD;
             treatment within a year to date;&#xD;
&#xD;
          -  Presence of other diseases (such as cancer, malignancies, congestive heart failure,&#xD;
             organ transplantation or candidate for it) or history of substance abuse (alcohol,&#xD;
             cocaine, heroin, etc.), poor protocol compliance or life expectancy of less than 1&#xD;
             year;&#xD;
&#xD;
          -  Allergic to one of following: aspirin, heparin, clopidogrel, sirolimus (rapamycin),&#xD;
             PLGA polymers, contrast agents and metal;&#xD;
&#xD;
          -  Severe liver and kidney dysfunction (ALT or AST level 3 times greater than the upper&#xD;
             limit of normal; eGFR &lt;30ml/min);&#xD;
&#xD;
          -  Patients participating in any other clinical trial and who have not completed&#xD;
             follow-up to the primary endpoint;&#xD;
&#xD;
          -  Study subjects with poor compliance judged by investigators, with poor possibility to&#xD;
             complete study in accordance with requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaling Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The General Hospital of Shenyang Military Region</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Baotou University</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia People'S Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'An Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The General Hospital of Shenyang Military Region</name>
      <address>
        <city>Area Of Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fu Wai Hospital, National Center for Cardiovascular Disease</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Sichuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TEDA International Cardiovascular Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 15, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>patients</keyword>
  <keyword>primary in situ CHD (de novo) lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

